Ausgabe 2/2007
Inhalt (12 Artikel)
The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis
Jing Jin, Hua Sun, Huailing Wei, Gengtao Liu
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line
Alan Pourpak, Robert T. Dorr, Ross O. Meyers, Marianne B. Powell, Steven P. Stratton
The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells
Tracy A. Brooks, Kieran L. O’Loughlin, Hans Minderman, Brian N. Bundy, Laurie A. Ford, Michael R. Vredenburg, Ralph J. Bernacki, Waldemar Priebe, Maria R. Baer
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer
S. J. Dawson, M. Michael, J. Biagi, K. F. Foo, M. Jefford, S. Y. Ngan, T. Leong, A. Hui, A. D. Milner, R. J. S. Thomas, J. R. Zalcberg
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
Luis H. Camacho, Jon Olson, William P. Tong, Charles W. Young, David R. Spriggs, Mark G. Malkin
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Thomas W. Flaig, Daniel L. Gustafson, Lih-Jen Su, Joseph A. Zirrolli, Frances Crighton, Gail S. Harrison, A. Scott Pierson, Rajesh Agarwal, L. Michael Glodé
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor
Amin M. Alousi, Ramesh Boinpally, Richard Wiegand, Ralph Parchment, Shirish Gadgeel, Lance K. Heilbrun, Antionette J. Wozniak, Pamela DeLuca, Patricia M. LoRusso
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma
Michael G. Smylie, Ralph Wong, Catalin Mihalcioiu, Chris Lee, Jean-Francois Pouliot
Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules
Harold J. Burstein, Beth Overmoyer, Rebecca Gelman, Paula Silverman, Jennifer Savoie, Kathryn Clarke, Leda Dumadag, Jerry Younger, Percy Ivy, Eric P. Winer
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
Matthew G. Fury, Andrew Zahalsky, Richard Wong, Ennapadam Venkatraman, Eric Lis, Lucy Hann, Timothy Aliff, William Gerald, Martin Fleisher, David G. Pfister
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study
Stefan von Delius, Florian Eckel, Stefan Wagenpfeil, Martina Mayr, Konrad Stock, Frank Kullmann, Florian Obermeier, Johannes Erdmann, Renate Schmelz, Stefan Quasthoff, Helmuth Adelsberger, Rainer Bredenkamp, Roland M. Schmid, Christian Lersch
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
Gonzalo Gomez-Abuin, Eric Winquist, Walter M. Stadler, Greg Pond, Pamela Degendorfer, John Wright, Malcolm J. Moore